THE U.S. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE WAS VALUED AT USD 3.05 BILLION IN 2021 AND IS EXPECTED TO REACH USD 4.55 BILLION BY 2027, GROWING AT A CAGR OF 6.90% DURING THE FORECAST PERIOD

The U.S. Assisted Reproductive Technology Market Research Report Includes Size, Share, Trends Analysis, Competitive Landscape, and Growth Potential

  • Type: Services (Source (Frozen Non-Donor, Fresh Non-Donor, Fresh Donor and Frozen Donor)
  • Age Group: Between 35 & 40 Years, Less Than 35 Years and Above 40 Years)
  • Technique: In Virto Fertilization (IVF), Frozen Embryo Transfer (FET), and Others)
  • Devices: Product (Consumables, Media, and Equipment)
  • End-User: (Fertility Clinics and Hospitals))

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share, & Forecast, 2022-2027 

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

193 Pages

icon-table

44 Tables

icon-chart

78 Charts

icon-region

1 Regions

icon-country

1 Countries

icon-company

53 Companies

icon-market

3 Market Segment

U.S. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 4.55 BILLION
Market Size (2021) USD 3.05 BILLION
CAGR (2022-2027) 6.90%
Base Year 2021
Forecast Year 2022-2027
Market Segments Type (Services (Source (Frozen Non-Donor, Fresh Non-Donor, Fresh Donor and Frozen Donor), Age Group (Between 35 & 40 Years, Less Than 35 Years and Above 40 Years) and Technique (In Virto Fertilization (IVF), Frozen Embryo Transfer (FET), and Others) and Devices (Product (Consumables, Media, and Equipment) and End-User (Fertility Clinics and Hospitals))
Geographic Analysis United States

MARKET INSIGHTS

The U.S. assisted reproductive technology market is expected to grow at a CAGR of over 6% from 2022 to 2027 and is expected to cross $4 billion by 2027 from $3 billion in 2021. Assisted reproductive technology (ART) is used for the treatment of infertility. It involves fertility treatments that handle both a man’s sperm and a woman’s egg. ART works by detaching eggs from a woman’s body. Then, the eggs are mixed with sperm to make embryos. Most of the time, ART procedures consist of surgically taking off the eggs from a woman’s ovaries, blending them with sperm in the laboratory, and then returning them to the woman’s body or donating them to another woman. The major factors propelling the growth of the U.S. assisted reproductive technology industry is the increasing prevalence of infertility, changing lifestyle of people causing infertility, the growing acceptance of ART procedure, and the rising number of fertility clinics.

Constant product innovations, technological advancements, and increasing end-user awareness drive the industry's growth. The significant players adopt several expansion and growth strategies such as partnerships, acquisitions, and product launches to increase their market presence. Perceiving a lucrative market, private equity firms are flowing money into building national chains of fertility clinics. The entry of venture capitalists and private equity is changing the overall fertility services industry. According to Arizton’s report, the global fertility test market was valued at USD 439.56 million in 2021 and is expected to grow at a CAGR of 7%. The globalization of healthcare facilities and the increasing popularity of fertility tourism are significant growth enablers of the global infertility treatment market.

TRENDS AND DEVELOPMENT

  • The growing number of single parents and same-sex couples is driving the growth of assisted reproductive technology market in the U.S. Governments of various countries are legalizing infertility treatment for same-sex couples and single parents.
  • Technological advancements and innovations in ART contribute to the United States assisted reproductive technology market growth. For instance, medical laser technology is now being employed across ART to decrease the procedure times and enhance conventional ART techniques' consistency and reproducibility.
  • Rising venture capital & private equity investment in infertility services drive the U.S. assisted reproductive technology industry. In 2017 alone, over 75 fertility-related firms received USD 178 million from private investors to grow Assisted Reproductive Technology Global Market.
  • Increasing financial assistance programs & employer benefits for infertility treatment contributes to industry growth. Many employers pay greater attention to personal health issues, especially infertility among employees, and offer various benefits, not just fertility leaves but also fertility allowances to get infertility treated.

MARKET SHARE & SEGMENTS

The frozen non-donor segment accounted for a significant share of more than 50% in 2021. The substantial share growth is due to fertility clinics' increased awareness of egg-freezing techniques among infertile couples. The IVF segment accounted for more than 80% share by technique because of its low-risk factor. Consumption growth is attributed to the increased and recurring usage of consumables during IVF procedures.

The fertility Clinics segment accounted for more than 70% of the US assisted reproductive technology market in 2021. The number of fertility clinics is increasing globally as the acceptance of fertility services is growing and at an all-time high in most countries. This increase in fertility clinics is catering to the growing demand for fertility services like IVF procedures among patients with infertility problems.

COMPETITIVE LANDSCAPE

  • The key players in assisted reproductive technology (ART) market are The Cooper Companies, Cook Medical, FUJIFILM Irvine Scientific, Hamilton Thorne, Merck Group, and Vitrolife.
  • Vendors may depend on strategic collaborations with end-users offering IVF procedures to promote their new products and establish long-term associations with their customers.
  • Key players with huge infrastructure and R&D support are expanding their footprint in the industry by implementing various marketing strategies to gain traction among end-users and increase their market presence.
  • Vendors should seek to strengthen their distribution by establishing company-owned distribution or sales networks or forming license or distribution contracts with regional vendors to expand product profit margins.

The U.S. assisted reproductive technology market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Segmentation by Type

  • Services
    • Source
      • Frozen Non-Donor
      • Fresh Non-Donor
      • Fresh Donor
      • Frozen Donor
  • Age Group
    • Between 35 & 40 Years
    • Less Than 35 Years
    • Above 40 Years
  • Technique
    • In Virto Fertilization (IVF)
    • Frozen Embryo Transfer (FET)
    • Others
  • Devices
    • Product
    • Consumables
    • Media
    • Equipment
  • End-user
    • Fertility Clinics
    • Hospitals

KEY INDUSTRY PLAYERS

  • Cook Medical
  • FUJIFILM Irvine Scientific
  • Hamilton Thorne
  • Merck Group
  • Vitrolife

Frequently Asked Questions

What is the total market worth of assisted reproductive technology market in U.S.?

The U.S. assisted reproductive technology market size was valued at USD 3.05 billion in 2021 and is expected to reach USD 4.55 billion by 2027, growing at a CAGR of 6.90% during the forecast period.

Which are the top manufacturers that hold the major share in assisted reproductive technology market in United States?

The key players in assisted reproductive technology (ART) market are The Cooper Companies, Cook Medical, FUJIFILM Irvine Scientific, Hamilton Thorne, Merck Group, and Vitrolife.

What are the key trends in the U.S. assisted reproductive technology (ART) market report?

Growing number of same sex couples, technological advancements, Rising Venture Capital & Private Equity Investment and increasing employee benefit schemes by companies for infertility treatment are driving U.S. assisted reproductive technology (ART) market

What are some market opportunities for emerging players to increase their industry share?

Emerging players may depend on strategic collaborations with end-users offering IVF procedures to promote their new products and establish long-term association with their customers. Players should also focus on their marketing strategies to reach most customers.

What is the anticipated CAGR of the assisted reproductive technology market in the forecast period?

The market is expected to grow at a CAGR of 6.90% between 2021 and 2027

Download Free Sample

The U.S. assisted reproductive technology (ART) market was valued at USD 3,050.0 million in 2021 and is expected to reach USD 4,551.53 million by 2027, growing at a CAGR of 6.90% during the forecast period.

Base Year: 2021

Forecast Year: 2022-2027

The study considers a detailed scenario of the present U.S. assisted reproductive technology (ART) market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

KEY MANUFACTURERS PROFILE

  • The Cooper Companies
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Cook Medical
  • FUJIFILM Irvine Scientific
  • Hamilton Thorne
  • Merck Group
  • Vitrolife

OTHER PROMINENT MANUFACTURERS

  • CARL ZEISS
    • Business Overview
    • Product Offerings
  • Esco Lifesciences
  • INVO Bioscience
  • Kitazato USA
  • Nidacon
  • Rocket Medical
  • Thermo Fisher Scientific
  • Thomas Medical

PROMINENT ART SERVICE PROVIDERS

  • The American Fertility California Corp.
    • Business Overview
    • Product Offerings
  • Angels Creation Reproductive Center (ACRC)
  • Aspire Houston Fertility Institute
  • Boston IVF
  • CARE Fertility
  • Carolinas Fertility Institute
  • CCRM Fertility
  • Center of Reproductive Medicine
  • Conceptions Reproductive Associates
  • Dallas-Fort Worth Fertility Associates
  • Extend Fertility
  • Fertility Center
  • Fertility Center of San Antonio
  • Infertility Texas
  • Innovative Fertility Center
  • Institute for Human Reproduction (IHR)
  • Kindbody
  • Main Line Fertility & Reproductive Medicine
  • Mayo Clinic
  • New Hope Fertility Center
  • Oma Fertility
  • Overlake Reproductive Health
  • Pacific Fertility Center
  • Pacific Reproductive Center
  • Reproductive Medicine Associates of Philadelphia
  • ReproMed Fertility Center
  • San Diego Fertility Center
  • Santa Barbara Fertility Center
  • Santa Monica Fertility
  • Sher Institutes for Reproductive Medicine
  • Southern California Reproductive Center (SCRC)
  • Tennessee Reproductive Medicine (TRM)
  • Texas Center for Reproductive Health
  • The Center for Fertility and Gynecology
  • The Fertility Center of Las Vegas
  • The Reproductive Medicine Group
  • UCLA Fertility and Reproductive Health Center
  • Western Fertility Institute
  • Wisconsin Fertility

Segmentation by Type

  • Services
    • Source
      • Frozen Non-Donor
      • Fresh Non-Donor
      • Fresh Donor
      • Frozen Donor
    • Age Group
      • Between 35 & 40 Years
      • Less Than 35 Years
      • Above 40 Years
    • Technique
      • In Virto Fertilization (IVF)
      • Frozen Embryo Transfer (FET)
      • Others
  • Devices
    • Product
    • Consumables
    • Media
    • Equipment
  • End-user
    • Fertility Clinics
    • Hospitals

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY SERVICE

4.3.2 MARKET SEGMENTATION BY DEVICE

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 OVERVIEW OF INFERTILITY & ART

7.2 TRENDS IN ART

8 MARKET OPPORTUNITIES & TRENDS

8.1 GROWING NUMBER OF SINGLE PARENTS AND SAME-SEX COUPLES

8.2 TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN ART

8.3 RISING VENTURE CAPITAL & PRIVATE EQUITY INVESTMENTS IN INFERTILITY SERVICES

8.4 INCREASING FINANCIAL ASSISTANCE PROGRAMS & EMPLOYER BENEFITS FOR INFERTILITY TREATMENT

9 MARKET GROWTH ENABLERS

9.1 INCREASING PREVALENCE OF INFERTILITY

9.2 RISING NUMBER OF FERTILITY CLINICS OFFERING FERTILITY SERVICES

9.3 CHANGING LIFESTYLES OF PEOPLE

9.4 INCREASING ACCEPTANCE OF ART PROCEDURES

10 MARKET RESTRAINTS

10.1 HIGH COST OF INFERTILITY TREATMENT

10.2 RISKS AND LIMITATIONS ASSOCIATED WITH INFERTILITY TREATMENT

10.3 ETHICAL CHALLENGES RELATED TO INFERTILITY TREATMENT

10.4 LACK OF STANDARDIZED GOVERNMENT REGULATIONS ON INFERTILITY TREATMENT

11 MARKET LANDSCAPE

11.1 MARKET OVERVIEW

11.2 MARKET SIZE & FORECAST

11.2.1 TYPE INSIGHTS

11.2.2 SOURCE INSIGHTS

11.2.3 AGE GROUP INSIGHTS

11.2.4 TECHNIQUE INSIGHTS

11.2.5 PRODUCT INSIGHTS

11.2.6 END-USER INSIGHTS

11.3 FIVE FORCES ANALYSIS

11.3.1 THREAT OF NEW ENTRANTS

11.3.2 BARGAINING POWER OF SUPPLIERS

11.3.3 BARGAINING POWER OF BUYERS

11.3.4 THREAT OF SUBSTITUTES

11.3.5 COMPETITIVE RIVALRY

12 TYPE

12.1 MARKET SNAPSHOT & GROWTH ENGINE

12.2 MARKET OVERVIEW

13 SERVICES

13.1 MARKET OVERVIEW

13.2 MARKET SIZE & FORECAST

13.3 ART SERVICES MARKET BY SOURCE

13.3.1 MARKET SNAPSHOT & GROWTH ENGINE

13.4 FROZEN NON-DONOR

13.4.1 MARKET SIZE & FORECAST

13.5 FRESH NON-DONOR

13.5.1 MARKET SIZE & FORECAST

13.6 FRESH DONOR

13.6.1 MARKET SIZE & FORECAST

13.7 FROZEN DONOR

13.7.1 MARKET SIZE & FORECAST

13.8 ART SERVICES MARKET BY AGE GROUP

13.8.1 MARKET SNAPSHOT & GROWTH ENGINE

13.9 BETWEEN 35 & 40 YEARS

13.9.1 MARKET SIZE & FORECAST

13.10 LESS THAN 35 YEARS

13.10.1 MARKET SIZE & FORECAST

13.11 ABOVE 40 YEARS

13.11.1 MARKET SIZE & FORECAST

13.12 ART SERVICES MARKET BY TECHNIQUE

13.12.1 MARKET SNAPSHOT & GROWTH ENGINE

13.13 IN VITRO FERTILIZATION (IVF)

13.13.1 MARKET SIZE & FORECAST

13.14 FROZEN EMBRYO TRANSFER (FET)

13.14.1 MARKET SIZE & FORECAST

13.15 OTHERS

13.15.1 MARKET SIZE & FORECAST

14 DEVICES

14.1 MARKET OVERVIEW

14.2 MARKET SIZE & FORECAST

14.3 ART DEVICES MARKET BY PRODUCT

14.3.1 MARKET SNAPSHOT & GROWTH ENGINE

14.3.2 CONSUMABLES: MARKET SIZE & FORECAST

14.3.3 MEDIA: MARKET SIZE & FORECAST

14.3.4 EQUIPMENT: MARKET SIZE & FORECAST

14.4 ART DEVICES MARKET BY END-USER

14.4.1 MARKET SNAPSHOT & GROWTH ENGINE

14.4.2 FERTILITY CLINICS: MARKET SIZE & FORECAST

14.4.3 HOSPITALS: MARKET SIZE & FORECAST

15 COMPETITIVE LANDSCAPE

15.1 COMPETITION OVERVIEW: ART DEVICE MANUFACTURERS

15.2 COMPETITION OVERVIEW: SERVICE PROVIDERS

15.3 MARKET SHARE ANALYSIS: MANUFACTURERS

15.3.1 THE COOPER COMPANIES

15.3.2 COOK MEDICAL

15.3.3 VITROLIFE

15.3.4 FUJIFILM IRVINE SCIENTIFIC

15.3.5 ROCKET MEDICAL

15.3.6 KITAZATO

15.3.7 MERCK GROUP

15.3.8 HAMILTON THORNE

15.4 MARKET SHARE ANALYSIS: ART SERVICE PROVIDERS

16 KEY MANUFACTURER PROFILES

16.1 THE COOPER COMPANIES

16.1.1 BUSINESS OVERVIEW

16.1.2 MAJOR PRODUCT OFFERINGS

16.1.3 KEY STRENGTHS

16.1.4 KEY STRATEGIES

16.1.5 KEY OPPORTUNITIES

16.2 COOK MEDICAL

16.2.1 BUSINESS OVERVIEW

16.2.2 MAJOR PRODUCT OFFERINGS

16.2.3 KEY STRATEGIES

16.2.4 KEY STRENGTHS

16.2.5 KEY OPPORTUNITIES

16.3 FUJIFILM IRVINE SCIENTIFIC

16.3.1 BUSINESS OVERVIEW

16.3.2 MAJOR PRODUCT OFFERINGS

16.3.3 KEY STRATEGIES

16.3.4 KEY STRENGTHS

16.3.5 KEY OPPORTUNITIES

16.4 HAMILTON THORNE

16.4.1 BUSINESS OVERVIEW

16.4.2 MAJOR PRODUCT OFFERINGS

16.4.3 KEY STRATEGIES

16.4.4 KEY STRENGTHS

16.4.5 KEY OPPORTUNITIES

16.5 MERCK GROUP

16.5.1 BUSINESS OVERVIEW

16.5.2 MAJOR PRODUCT OFFERINGS

16.5.3 KEY STRATEGIES

16.5.4 KEY STRENGTHS

16.5.5 KEY OPPORTUNITIES

16.6 VITROLIFE

16.6.1 BUSINESS OVERVIEW

16.6.2 MAJOR PRODUCT OFFERINGS

16.6.3 KEY STRATEGIES

16.6.4 KEY STRENGTHS

16.6.5 KEY OPPORTUNITIES

17 OTHER PROMINENT MANUFACTURERS

17.1 CARL ZEISS

17.1.1 BUSINESS OVERVIEW

17.1.2 MAJOR PRODUCT OFFERINGS

17.2 ESCO LIFESCIENCES

17.2.1 BUSINESS OVERVIEW

17.2.2 MAJOR PRODUCT OFFERINGS

17.3 INVO BIOSCIENCE

17.3.1 BUSINESS OVERVIEW

17.3.2 MAJOR PRODUCT OFFERINGS

17.4 KITAZATO

17.4.1 BUSINESS OVERVIEW

17.4.2 MAJOR PRODUCT OFFERINGS

17.5 NIDACON

17.5.1 BUSINESS OVERVIEW

17.5.2 MAJOR PRODUCT OFFERINGS

17.6 ROCKET MEDICAL

17.6.1 BUSINESS OVERVIEW

17.6.2 MAJOR PRODUCT OFFERINGS

17.7 THERMO FISHER SCIENTIFIC

17.7.1 BUSINESS OVERVIEW

17.7.2 MAJOR PRODUCT OFFERINGS

17.8 THOMAS MEDICAL

17.8.1 BUSINESS OVERVIEW

17.8.2 MAJOR PRODUCT OFFERINGS

18 PROMINENT ART SERVICE PROVIDERS

18.1 THE AMERICAN FERTILITY CALIFORNIA CORP.

18.1.1 BUSINESS OVERVIEW

18.2 ANGELS CREATION REPRODUCTIVE CENTER

18.2.1 BUSINESS OVERVIEW

18.3 ASPIRE HOUSTON FERTILITY INSTITUTE

18.3.1 BUSINESS OVERVIEW

18.4 BOSTON IVF

18.4.1 BUSINESS OVERVIEW

18.5 CARE FERTILITY

18.5.1 BUSINESS OVERVIEW

18.6 CAROLINAS FERTILITY INSTITUTE

18.6.1 BUSINESS OVERVIEW

18.7 CCRM FERTILITY

18.7.1 BUSINESS OVERVIEW

18.8 CENTER OF REPRODUCTIVE MEDICINE

18.8.1 BUSINESS OVERVIEW

18.9 CONCEPTIONS REPRODUCTIVE ASSOCIATES

18.9.1 BUSINESS OVERVIEW

18.10 DALLAS-FORT WORTH FERTILITY ASSOCIATES

18.10.1 BUSINESS OVERVIEW

18.11 EXTEND FERTILITY

18.11.1 BUSINESS OVERVIEW

18.12 FERTILITY CENTER

18.12.1 BUSINESS OVERVIEW

18.13 FERTILITY CENTER OF SAN ANTONIO

18.13.1 BUSINESS OVERVIEW

18.14 INFERTILITY TEXAS

18.14.1 BUSINESS OVERVIEW

18.15 INNOVATIVE FERTILITY CENTER

18.15.1 BUSINESS OVERVIEW

18.16 INSTITUTE FOR HUMAN REPRODUCTION

18.16.1 BUSINESS OVERVIEW

18.17 KINDBODY

18.17.1 BUSINESS OVERVIEW

18.18 MAIN LINE FERTILITY & REPRODUCTIVE MEDICINE

18.18.1 BUSINESS OVERVIEW

18.19 MAYO CLINIC

18.19.1 BUSINESS OVERVIEW

18.20 NEW HOPE FERTILITY CENTER

18.20.1 BUSINESS OVERVIEW

18.21 OMA FERTILITY

18.21.1 BUSINESS OVERVIEW

18.22 OVERLAKE REPRODUCTIVE HEALTH

18.22.1 BUSINESS OVERVIEW

18.23 PACIFIC FERTILITY CENTER

18.23.1 BUSINESS OVERVIEW

18.24 PACIFIC REPRODUCTIVE CENTER

18.24.1 BUSINESS OVERVIEW

18.25 REPRODUCTIVE MEDICINE ASSOCIATES OF PHILADELPHIA

18.25.1 BUSINESS OVERVIEW

18.26 REPROMED FERTILITY CENTER

18.26.1 BUSINESS OVERVIEW

18.27 SAN DIEGO FERTILITY

18.27.1 BUSINESS OVERVIEW

18.28 SANTA BARBARA FERTILITY CENTER

18.28.1 BUSINESS OVERVIEW

18.29 SANTA MONICA FERTILITY

18.29.1 BUSINESS OVERVIEW

18.30 SHER INSTITUTES FOR REPRODUCTIVE MEDICINE

18.30.1 BUSINESS OVERVIEW

18.31 SOUTHERN CALIFORNIA REPRODUCTIVE CENTER

18.31.1 BUSINESS OVERVIEW

18.32 TENNESSEE REPRODUCTIVE MEDICINE

18.32.1 BUSINESS OVERVIEW

18.33 TEXAS CENTER FOR REPRODUCTIVE HEALTH

18.33.1 BUSINESS OVERVIEW

18.34 THE CENTER FOR FERTILITY AND GYNECOLOGY

18.34.1 BUSINESS OVERVIEW

18.35 THE FERTILITY CENTER OF LAS VEGAS

18.35.1 BUSINESS OVERVIEW

18.36 THE REPRODUCTIVE MEDICINE GROUP

18.36.1 BUSINESS OVERVIEW

18.37 UCLA HEALTH

18.37.1 BUSINESS OVERVIEW

18.38 WESTERN FERTILITY INSTITUTE

18.38.1 BUSINESS OVERVIEW

18.39 WISCONSIN FERTILITY INSTITUTE

18.39.1 BUSINESS OVERVIEW

19 REPORT SUMMARY

19.1 KEY TAKEAWAYS

19.2 STRATEGIC RECOMMENDATIONS

20 QUANTITATIVE SUMMARY

20.1 MARKET BY TYPE

20.2 MARKET BY ART SERVICES

20.2.1 ART SERVICES: SOURCE SEGMENTATION

20.2.2 ART SERVICES: AGE GROUP SEGMENTATION

20.2.3 ART SERVICES: TECHNIQUE SEGMENTATION

20.3 MARKET BY ART DEVICES

20.3.1 ART DEVICES: PRODUCT SEGMENTATION

20.3.2 ART DEVICES: END-USER SEGMENTATION

21 APPENDIX

21.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021

EXHIBIT 3 SOME FACTS ABOUT CONCEPTION AND FERTILITY

EXHIBIT 4 IMPACT OF GROWING NUMBER OF SINGLE PARENTS AND SAME-SEX COUPLES

EXHIBIT 5 SAME-SEX MARRIED COUPLES IN THE US DURING 2010-2019

EXHIBIT 6 IMPACT OF TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN ART

EXHIBIT 7 IMPACT OF RISING VENTURE CAPITAL & PRIVATE EQUITY INVESTMENTS IN INFERTILITY SERVICES

EXHIBIT 8 IMPACT OF INCREASING FINANCIAL ASSISTANCE PROGRAMS & EMPLOYER BENEFITS FOR INFERTILITY TREATMENT

EXHIBIT 9 IMPACT OF INCREASING PREVALENCE OF INFERTILITY

EXHIBIT 10 IMPACT OF RISING NUMBER OF FERTILITY CLINICS OFFERING FERTILITY SERVICES

EXHIBIT 11 IMPACT OF CHANGING LIFESTYLES OF PEOPLE

EXHIBIT 12 IMPACT OF INCREASING ACCEPTANCE OF ART PROCEDURES

EXHIBIT 13 NUMBER OF ART CYCLES PERFORMED IN THE US 2012-2029 (IN 1,000S)

EXHIBIT 14 PERCENTAGE OF INFANTS BORN FROM ART PROCEDURES PERFORMED IN 2017 WHO WERE PRETERM OR WITH LOW BIRTH WEIGHT—US 2017 OR 2018

EXHIBIT 15 IMPACT OF HIGH COST OF INFERTILITY TREATMENT

EXHIBIT 16 IMPACT OF RISKS AND LIMITATIONS ASSOCIATED WITH INFERTILITY TREATMENT

EXHIBIT 17 ETHICAL CHALLENGES RELATED TO INFERTILITY TREATMENTS

EXHIBIT 18 ETHICAL AND LEGAL CHALLENGES

EXHIBIT 19 IMPACT OF LACK OF STANDARDIZED GOVERNMENT REGULATIONS ON INFERTILITY TREATMENT

EXHIBIT 20 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 2021–2027 ($ MILLION)

EXHIBIT 21 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE

EXHIBIT 22 US ASSISTED REPRODUCTIVE TECHNOLOGY SERVICES MARKET BY SOURCE

EXHIBIT 23 US ASSISTED REPRODUCTIVE TECHNOLOGY SERVICES MARKET BY AGE GROUP

EXHIBIT 24 US ASSISTED REPRODUCTIVE TECHNOLOGY SERVICES MARKET BY TECHNIQUE

EXHIBIT 25 US ASSISTED REPRODUCTIVE TECHNOLOGY DEVICES MARKET BY PRODUCT

EXHIBIT 26 US ASSISTED REPRODUCTIVE TECHNOLOGY DEVICES MARKET BY END-USER

EXHIBIT 27 FIVE FORCES ANALYSIS 2021

EXHIBIT 28 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 29 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE

EXHIBIT 30 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE: INCREMENTAL GROWTH

EXHIBIT 31 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY SERVICES

EXHIBIT 32 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY SERVICES 2021–2027 ($ MILLION)

EXHIBIT 33 INCREMENTAL GROWTH BY SOURCE 2021 & 2027

EXHIBIT 34 US ART SERVICES FROZEN NON-DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 35 US ART SERVICES FROZEN NON-DONOR MARKET 2021–2027 ($ MILLION)

EXHIBIT 36 US ART SERVICES FRESH NON-DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 37 US ART SERVICES FRESH NON-DONOR MARKET 2021–2027 ($ MILLION)

EXHIBIT 38 US ART SERVICES FRESH DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 39 US ART SERVICES FRESH DONOR MARKET 2021–2027 ($ MILLION)

EXHIBIT 40 US ART SERVICES FROZEN DONOR MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 41 US ART SERVICES FROZEN DONOR MARKET 2021–2027 ($ MILLION)

EXHIBIT 42 INCREMENTAL GROWTH BY AGE GROUP 2021 & 2027

EXHIBIT 43 US ART SERVICES BETWEEN 35 & 40 YEARS OF AGE MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 44 US ART SERVICES BETWEEN 35 & 40 YEARS OF AGE MARKET 2021–2027 ($ MILLION)

EXHIBIT 45 US ART SERVICES LESS THAN 35 YEARS OF AGE MARKET 2021–2027 ($ MILLION)

EXHIBIT 46 US ART SERVICES ABOVE 40 YEARS OF AGE MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 47 PERCENTAGE OF LIVE BIRTHS PER CYCLE IN WOMEN 40 YEARS & ABOVE

EXHIBIT 48 US ART SERVICES ABOVE 40 YEARS OF AGE MARKET 2021–2027 ($ MILLION)

EXHIBIT 49 INCREMENTAL GROWTH BY TECHNIQUE 2021 & 2027

EXHIBIT 50 US ART SERVICES IN VITRO FERTILIZATION (IVF) MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 51 IVF OVERVIEW

EXHIBIT 52 INFERTILITY PROBLEMS FOR WHICH IVF MAY BE REQUIRED

EXHIBIT 53 US ART SERVICES IN VITRO FERTILIZATION (IVF) MARKET 2021–2027 ($ MILLION)

EXHIBIT 54 US ART SERVICES FROZEN EMBRYO TRANSFER (FET) MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 55 US ART SERVICES FROZEN EMBRYO TRANSFER (FET) MARKET 2021–2027 ($ MILLION)

EXHIBIT 56 US ART SERVICES OTHER TECHNIQUES MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 57 US ART SERVICES OTHER TECHNIQUES MARKET 2021–2027 ($ MILLION)

EXHIBIT 58 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY DEVICES

EXHIBIT 59 US ART DEVICES MARKET 2021–2027 ($ MILLION)

EXHIBIT 60 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027

EXHIBIT 61 US ART DEVICES CONSUMABLES MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 62 US ART DEVICES CONSUMABLES MARKET 2021–2027 ($ MILLION)

EXHIBIT 63 US ART DEVICES MEDIA MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 64 US ART DEVICES MEDIA MARKET 2021–2027 ($ MILLION)

EXHIBIT 65 US ART DEVICES EQUIPMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 66 US ART DEVICES EQUIPMENT MARKET 2021–2027 ($ MILLION)

EXHIBIT 67 INCREMENTAL GROWTH BY END-USER 2021 & 2027

EXHIBIT 68 US ART DEVICES FERTILITY CLINICS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 69 US ART DEVICES FERTILITY CLINICS MARKET 2021–2027 ($ MILLION)

EXHIBIT 70 US ART DEVICES HOSPITALS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 71 US ART DEVICES HOSPITALS MARKET 2021–2027 ($ MILLION)

EXHIBIT 72 THE COOPER COMPANIES: ANNUAL REVENUES 2019-2021 ($ MILLION)

EXHIBIT 73 THE COOPER COMPANIES BUSINESS SEGMENTS: ANNUAL REVENUE 2019-2021 ($ MILLION)

EXHIBIT 74 THE COOPERS COMPANIES REVENUE SPLIT: COOPERSURGICAL BUSINESS SEGMENT 2020 (%)

EXHIBIT 75 MERCK GROUP: ANNUAL REVENUE 2018-2020 ($ BILLION)

EXHIBIT 76 MERCK GROUP BUSINESS SEGMENTS: ANNUAL REVENUE 2019-2020 ($ MILLION)

EXHIBIT 77 VITROLIFE: ANNUAL REVENUE 2018-2020 ($ MILLION)

EXHIBIT 78 VITROLIFE BY REGION: SALES REVENUE 2019-2020 ($ MILLION)

LIST OF TABLES

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2015−2021

TABLE 3 SOME POPULAR FERTILITY TREATMENT LOANS IN THE US

TABLE 4 SOME OF THE MOST PREVALENT FERTILITY TREATMENT GRANTS IN THE US

TABLE 5 FERTILITY RELATED CONDITIONS ASSOCIATED WITH OBESITY IN MEN

TABLE 6 FERTILITY RELATED CONDITIONS RELATED TO OBESITY IN FEMALES

TABLE 7 PROBABILITIES OF A LIVE BIRTH BY FIFTH IVF CYCLE

TABLE 8 COSTS OF VARIOUS INFERTILITY TREATMENT OPTIONS

TABLE 9 TOP FIVE IVF CLINICS FOR WOMEN AGED UNDER 35 (NON-DONOR EGGS)

TABLE 10 TOP FIVE IVF CLINICS FOR WOMEN AGED OVER 42 (NON-DONOR EGGS)

TABLE 11 ART CLINICAL OUTCOMES IN WOMEN ABOVE 40 YEARS

TABLE 12 AVERAGE IVF SUCCESS RATE IN THE US FOR FRESH EMBRYOS

TABLE 13 AVERAGE IVF SUCCESS RATE IN THE US FOR THAWED EMBRYOS

TABLE 14 SOME PROMINENT PLAYERS IN THE ART DEVICES MARKET OFFERING CONSUMABLES

TABLE 15 MEDIA OFFERINGS BY MAJOR PLAYERS

TABLE 16 TYPES OF MICROSCOPES USED IN ART PROCEDURES

TABLE 17 VARIOUS TYPES OF IMAGING MODALITIES USED IN ART PROCEDURES

TABLE 18 LIST OF TOP FERTILITY CLINICS IN THE US

TABLE 19 THE COOPER COMPANIES: PRODUCT OFFERINGS

TABLE 20 COOK MEDICAL: MAJOR PRODUCT OFFERINGS

TABLE 21 FUJIFILM IRVINE SCIENTIFIC: MAJOR PRODUCT OFFERINGS

TABLE 22 HAMILTON THORNE: MAJOR PRODUCT OFFERINGS

TABLE 23 MERCK GROUP: MAJOR PRODUCT OFFERINGS

TABLE 24 VITROLIFE: MAJOR PRODUCT OFFERINGS

TABLE 25 CARL ZEISS: MAJOR PRODUCT OFFERINGS

TABLE 26 ESCO LIFESCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 27 INVO BIOSCIENCE: MAJOR PRODUCT OFFERINGS

TABLE 28 KITAZATO: MAJOR PRODUCT OFFERINGS

TABLE 29 NIDACON: MAJOR PRODUCT OFFERINGS

TABLE 30 ROCKET MEDICAL: MAJOR PRODUCT OFFERINGS

TABLE 31 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS

TABLE 32 THOMAS MEDICAL: MAJOR PRODUCT OFFERINGS

TABLE 33 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE 2021−2027 ($ MILLION)

TABLE 34 US ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TYPE 2021−2027 (%)

TABLE 35 US ART SERVICES MARKET BY SOURCE 2021−2027 ($ MILLION)

TABLE 36 US ART SERVICES MARKET BY SOURCE 2021−2027 (%)

TABLE 37 US ART SERVICES MARKET BY AGE GROUP 2021−2027 ($ MILLION)

TABLE 38 US ART SERVICES MARKET BY AGE GROUP 2021−2027 (%)

TABLE 39 US ART SERVICES MARKET BY TECHNIQUE 2021−2027 ($ MILLION)

TABLE 40 US ART SERVICES MARKET BY TECHNIQUE 2021−2027 (%)

TABLE 41 US ART DEVICES MARKET BY PRODUCT 2021−2027 ($ MILLION)

TABLE 42 US ART DEVICES MARKET BY PRODUCT 2021−2027 (%)

TABLE 43 US ART DEVICES MARKET BY END-USER 2021−2027 ($ MILLION)

TABLE 44 US ART DEVICES MARKET BY END-USER 2021−2027 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date